However, further experiments and investigations focused on additional clinical samples are essential to understand the seemingly distinct BACH2–PRDM1 mediated regulatory mechanisms in DLBCL and CLL. This evidence concerns the gene PRDM1 and B-cell chronic lymphocytic leukemia.